- Home
- FBRX vs MYO Comparison
FBRX vs MYO Comparison
Compare FBRX & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- MYO
- Stock Information
- Founded
- FBRX N/A
- MYO 2004
- Country
- FBRX United States
- MYO United States
- Employees
- FBRX N/A
- MYO N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- MYO Industrial Specialties
- Sector
- FBRX Health Care
- MYO Health Care
- Exchange
- FBRX Nasdaq
- MYO Nasdaq
- Market Cap
- FBRX 154.5M
- MYO 153.0M
- IPO Year
- FBRX N/A
- MYO 2017
- Fundamental
- Price
- FBRX $11.60
- MYO $2.12
- Analyst Decision
- FBRX Strong Buy
- MYO Strong Buy
- Analyst Count
- FBRX 2
- MYO 3
- Target Price
- FBRX $61.00
- MYO $9.67
- AVG Volume (30 Days)
- FBRX 73.6K
- MYO 695.7K
- Earning Date
- FBRX 08-13-2025
- MYO 08-05-2025
- Dividend Yield
- FBRX N/A
- MYO N/A
- EPS Growth
- FBRX N/A
- MYO N/A
- EPS
- FBRX N/A
- MYO N/A
- Revenue
- FBRX N/A
- MYO $38,628,624.00
- Revenue This Year
- FBRX N/A
- MYO $55.29
- Revenue Next Year
- FBRX N/A
- MYO $27.18
- P/E Ratio
- FBRX N/A
- MYO N/A
- Revenue Growth
- FBRX N/A
- MYO 97.60
- 52 Week Low
- FBRX $4.11
- MYO $1.85
- 52 Week High
- FBRX $28.68
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- FBRX 53.91
- MYO 39.80
- Support Level
- FBRX $10.02
- MYO $1.85
- Resistance Level
- FBRX $10.99
- MYO $2.22
- Average True Range (ATR)
- FBRX 0.86
- MYO 0.14
- MACD
- FBRX -0.06
- MYO 0.05
- Stochastic Oscillator
- FBRX 60.78
- MYO 50.47
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).